Development of a novel IGRA assay to test T cell responsiveness to HBV antigens in whole blood of chronic Hepatitis B patients

Table 2 Positive and negative controls

Assay	NaCl (negative control)^a		SEB (1. positive control)^a		CEFT (2. positive control)^a
Assay	IFNγ [pg/ml]	IL2 [pg/ml]	IFNγ [pg/ml]	IL2 [pg/ml]	IFNγ [pg/ml]	IL2 [pg/ml]	N
Group
HC^b	8 ± 2	2 ± 1	66,537 ± 8485	22,762 ± 1399	1681 ± 361	125 ± 36	80
AHB^b	15 ± 5	3 ± 1	45,083 ± 14,487	10,737 ± 2148	458 ± 278	22 ± 11	8
CHB^b, NUC treatment naive	41 ± 22	1 ± 1	65,734 ± 8837	18,439 ± 1244	1490 ± 669	220 ± 173	40
CHB^b, NUC treated	17 ± 6	2 ± 1	107,200 ± 30,799	20,838 ± 1357	3186 ± 1383	318 ± 293	32

^aThe data are shown as means ± standard error of mean (S.E.M.). SEB and CEFT values are given after deduction of background values (NaCl, negative control)
^bHC = healthy controls, AHB = acute hepatitis B, CHB = chronic hepatitis B

ISSN: 1479-5876